Tenderwize
Retour à la recherche

Conclusion of non-exclusive discount agreement for Fentanyl

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jan 31, 2028 · 521 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Fentanyl (ATC-Code nach WHO: N02AB03)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

The buyer may terminate the Open-House process early if an exclusive discount agreement is signed. Existing agreements...

No minimum purchase quantities; actual demand depends on prescription behavior and patient numbers, leading to unpredic...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Conclusion of non-exclusive discount agreements for pharmaceutical products with the active substance Fentanyl (ATC N02AB03).
  • Limited to sublingual tablets and lozenges.
Afficher le résumé complet

Non-exclusive pharmaceutical discount agreement (Rabattvereinbarung) under § 130a(8) SGB V for the active substance Fentanyl in sublingual tablet and lozenge dosage forms. The agreement is concluded via an Open-House model, meaning any interested pharmaceutical company meeting the conditions can participate without exclusivity. No minimum purchase quantities are guaranteed. The contract runs until 31 January 2028. Participation is via the DTVP portal with strict confidentiality of tender documents.

Risques

The buyer may terminate the Open-House process early if an exclusive discount agreement is signed. Existing agreements...

No minimum purchase quantities; actual demand depends on prescription behavior and patient numbers, leading to unpredic...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical undertaking within the meaning of § 4(18) AMG for the offered medicinal products.

Eligibility

  • Must submit a self-declaration on the absence of exclusion grounds (§§ 123, 124 GWB).

Administrative

  • Must submit a self-declaration on compliance with EU sanctions against Russia (Art. 5k of Regulation (EU) 833/2014).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Conclusion of non-exclusive discount agreement for Fentanyl

Non-exclusive discount agreement for Fentanyl (ATC N02AB03) in sublingual tablet and lozenge forms under an Open-House model. No individual negotiations, no exclusivity, no minimum volume guarantee. Contract end date: 31 January 2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jun 2026 - Jan 2028

Catégorie

Pharmaceutical products

Date limite

Expired Jun 04, 2026

Détails de la procédure

Date de publication
07 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
240015-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30